REDWOOD CITY, Calif., Nov. 22, 2016 (GLOBE NEWSWIRE) — OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, announced that Sunil Patel, Chief Financial Officer, Senior Vice President, Corporate Development and Finance, will speak at the 28th Annual Piper Jaffray Healthcare Conference in New York on Tuesday, November 29, 2016 at 3:00 pm Eastern Time.
A live webcast of each presentation will be available through the OncoMed website in the Investor Relations section. The webcast will also be archived and available for replay for up to 45 days.
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics. OncoMed has internally discovered a broad pipeline of investigational drugs intended to address the fundamental biology driving cancer’s growth, recurrence and metastases. Demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), anti-DLL4/VEGF bispecific antibody (OMP-305B83), vantictumab (anti-FZD7, OMP-18R5), ipafricept (FZD8-Fc, OMP-54F28), anti-RSPO3 (OMP-131R10) and an undisclosed immuno-oncology candidate (I/O#2) are part of the company’s strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK). OncoMed is independently developing brontictuzumab (anti-Notch1, OMP-52M51) and GITRL-Fc, as well as continuing to pursue new drug discovery research efforts. For further information about OncoMed Pharmaceuticals, please see www.oncomed.com.
CONTACT: Contact: OncoMed Pharmaceuticals Michelle Corral Investor Relations and Corporate Communications michelle.corral@oncomed.com (650) 995-8373
